MDS Diagnosis and Management:
Experts Address Common Pitfalls and Challenges
A Series of CME Podcasts
 |
FACULTY:B. Douglas Smith, MD (Bio) |
DISCLOSURES:Speaker: Celgene |
 |
FACULTY:Daniel J. DeAngelo, MD, PhD (Bio) |
DISCLOSURES:Speaker: Bristol-Myers Squibb, Celgene, Novartis, Enzon Pharmaceuticals |
Rapid progress has been made in recent years, in both our understanding of and treatment options for the myelodysplastic syndromes (MDS). Appropriate diagnosis of the disease must be made, however, before these advances can be applied. Unfortunately, many practicing hematologists and oncologists are unclear about making a definitive diagnosis. Following diagnosis, clinicians continue to have questions related to patient management: Is this patient appropriate for stem cell transplantation? When do I begin treatment? Which targeted agent is most appropriate? Hematologists and oncologists treating MDS need to have a firm understanding of the diagnostic criteria, patient selection considerations, and management strategies using the newest agents in MDS therapy, in order to optimize outcomes for those suffering from this disease.
These CME podcasts will address the common pitfalls and challenges experienced by practicing hematologists and oncologists in the diagnosis and management of MDS. Utilizing an interview format, experts in MDS provide evidence and insights focusing on commonly asked questions and areas of confusion in the community. Participants will gain practical knowledge on the diagnosis and management of MDS, with an eye to improving clinical outcomes.
TARGET AUDIENCE
This program was developed for Hematologists who treat patients with MDS and other clinicians involved in the care of MDS patients.
LEARNING OBJECTIVES
At the conclusion of these activities, participants should be able to:
- Diagnose a patient with MDS
- Select patients appropriate for stem cell transplantation
- Develop a treatment strategy utilizing FDA-approved agents for MDS
ACCREDITATION STATEMENTS
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
The Potomac Center for Medical Education designates this educational activity for a maximum of 0.25 AMA PRA Category I credit(s)™ per podcast. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians have the opportunity to earn up to 0.75 AMA PRA Category I credit(s)™ by completing the series.
DISCLOSURE
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
B. Douglas Smith, MD: Speaker: Celgene
Daniel J. DeAngelo, MD, PhD: Speaker: Bristol-Myers Squibb, Celgene, Novartis, Enzon Pharmaceuticals
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests: Laurie Frueh, MD; Kathy Merlo; Brad Pine; Donna Fucello; Blair St. Amand; Elizabeth Griffiths, MD: Nothing to Disclose.
FDA Disclosure
The contents of some CME/CE activities may contain discussions of non-approved or off label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
By clicking this button you are agreeing that you have read and understood the CME Statements above.
TODAY'S MDS PATIENT:
Practical Approaches to New Therapeutic Options
A CME/CE Webcourse Focusing on Myelodysplastic Syndromes. This stimulating webcourse will explore fundamental clarifying developments in diagnosis, classification, and treatment of myelodysplastic syndromes (MDS).
|
MODERATED BY:B. Douglas Smith, MD (Bio) |
DISCLOSURES:Speaker: Celgene |
 |
FACULTY:Harry P. Erba, MD, PhD (Bio) |
DISCLOSURES:Investigator: Novartis, Wyeth, Genzyme, Cephalon, Xanthus, Kanisa, Cell Therapeutics, Pharmion |
 |
FACULTY:Erin P. Demakos, RN, CCRC (Bio) |
DISCLOSURES:Speaker: Pharmion, MDS Foundation |
INTRODUCTION
Classification and Risk Stratification in MDS
PRESENTATION 1
MDS Treatment: Practical Therapeutic Options and Approaches
PRESENTATION 2
Managing the MDS Patient Through Therapy
TARGET AUDIENCE
This activity is intended for hematologists, nurses, and other healthcare professionals caring for patients at risk of myelodysplastic syndromes.
LEARNING OBJECTIVES
At the conclusion of these activities, participants should be able to:
- Review the therapeutic approaches to MDS management using IPSS risk stratification
- Cite key clinical data regarding the safety and efficacy of various MDS treatment options
- Describe the typical dosing cycles of hypomethylating agents required for normalization of gene expression in MDS patients
- Initiate appropriate steps to reduce the frequency of adverse events and manage adverse events in MDS therapies
ACCREDITATION
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is co-provided between Potomac Center for Medical Education and Anthony J. Jannetti, Inc.
Anthony J. Jannetti, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
DISCLOSURE
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
The following staff members of the Potomac Center for Medical Education involved in the development of content for this activity disclosed that they have no relevant financial relationships: Barry Watkins, PhD, Medical Science Liaison, disclose Stephanie Stowell, MPhil, Medical Writer, Donna Fucello, Vice President, Clinical Education Division & Accreditation Services, Blair St. Amand, Editor, Dana Simpler, MD, external medical reviewer.
CREDIT DESIGNATION
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anthony J. Jannetti, Inc. designates this program for 1.25 CE contact hours. Participants should claim only those contact hours actually spent in the educational activity.
FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Please Note:
In order to view these presentations, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
